Search PLX
Protalix BioTherapeutics, Inc.
NYSE · CIK 1006281
Last close2.71
Daily change+0.03 (1.12%)
10 Years gain-52.46%
Dividends TTM0
Dividend yield0.00%
Fundamental Analysis
PLX · STANDARD
SIC 2836 · Biological Products, (No Diagnostic Substances) · Fiscal year end 1231
Fundamental
67.8Momentum
100.0Acceleration
100.0Confidence
77.0Annual Revenue17
Quarterly Revenue55
Annual CFO17
Balance SheetAvailable
RankingEligible
Score Breakdown
Growth9.0 / 25
Quality20.4 / 25
Capital Efficiency20.0 / 20
Balance Sheet15.0 / 15
Shareholder Economics0.0 / 10
Forward Indicators0.0 / 5
Signals
Gross margin expansionGross margin improved by 33.2446 percentage points.
Operating leverageOperating margin improved by 49.8323 percentage points.
Net debt reductionNet debt declined versus the comparison period.
Warnings
Receivables anomaly · MEDIUMAccounts receivable growth is materially above revenue growth.
Heavy share dilution · HIGHDiluted share count increased 7.7641%.
Key Metrics
Revenue Growth TTM92.42%OK
Revenue CAGR 3Y3.45%OK
Gross Margin70.07%OK
Operating Margin33.41%OK
FCF Marginn/aMISSING
FCF Growthn/aINSUFFICIENT_HISTORY
ROIC70.46%OK
Incremental Operating Margin 3Y123.83%OK
Net Debt / CFOn/aNOT_MEANINGFUL
Diluted Share Growth 1Y7.76%OK
SBC / Revenuen/aMISSING
SBC / FCFn/aNOT_MEANINGFUL
Financial History
| Period | Revenue | Gross Profit | Operating Income | CFO | FCF | Gross Margin | Op Margin | FCF Margin | ROIC | Shares |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025 FY Dec 31, 2025 | $52.74M | $25.75M | -$5.50M | -$11.99M | -$13.63M | 48.82% | -10.43% | -25.84% | -15.25% | 78.55M |
| 2025 FY Dec 31, 2024 | $53.40M | $29.08M | $3.92M | $8.67M | $7.39M | 54.46% | 7.34% | 13.84% | 16.56% | 81.06M |
| 2025 FY Dec 31, 2023 | $65.49M | $42.51M | $10.46M | -$1.32M | -$2.47M | 64.91% | 15.97% | -3.77% | n/a | 82.42M |
| 2024 FY Dec 31, 2022 | $47.64M | $28.05M | -$13.01M | -$25.00M | -$25.63M | 58.87% | -27.32% | -53.8% | n/a | 48.47M |
| 2023 FY Dec 31, 2021 | $38.35M | $22.00M | -$20.46M | -$10.29M | -$11.74M | 57.37% | -53.36% | -30.62% | n/a | 44.14M |
Formula Trace
| Metric | Value | Formula | Status | Source |
|---|---|---|---|---|
| Revenue TTM | $87.16M | sum latest 4 fiscal quarters Revenue | OK | 0001104659-26-094444, 0001104659-25-110824 |
| Revenue Growth TTM | 92.42% | Revenue_TTM / Revenue_TTM_1Y_ago - 1 | OK | 0001104659-26-094444, 0001104659-25-110824 |
| Revenue CAGR 3Y | 3.45% | (Revenue_current / Revenue_3Y_ago)^(1/3) - 1 | OK | 0001104659-26-029858 |
| Revenue CAGR 5Y | -3.46% | (Revenue_current / Revenue_5Y_ago)^(1/5) - 1 | OK | 0001104659-26-029858 |
| Gross Profit CAGR 3Y | -2.81% | (GrossProfit_current / GrossProfit_3Y_ago)^(1/3) - 1 | OK | 0001104659-26-029858 |
| Operating Income Growth | n/a | OperatingIncome_current / OperatingIncome_prior_year - 1 | INSUFFICIENT_HISTORY | 0001104659-26-094444, 0001104659-25-110824 |
| FCF Growth | n/a | FCF_current / FCF_prior_year - 1 | INSUFFICIENT_HISTORY | derived |
| Revenue Growth Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Profit Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Operating Income Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| FCF Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Margin | 70.07% | Gross Profit / Revenue | OK | 0001104659-26-094444, 0001104659-25-110824 |
| Operating Margin | 33.41% | Operating Income / Revenue | OK | 0001104659-26-094444, 0001104659-25-110824 |
| ROIC | 70.46% | NOPAT / Average Invested Capital | OK | 0001104659-26-094444, 0001104659-25-110824 |
| Net Debt / CFO | n/a | Net Debt / CFO | NOT_MEANINGFUL | 0001104659-26-094444 |
| Current Ratio | 2.94x | Current Assets / Current Liabilities | OK | derived |
| Revenue per Diluted Share | $1.06 | Revenue / Diluted Shares | OK | 0001104659-26-094444, 0001104659-25-110824 |
| SBC / FCF | n/a | SBC / FCF | NOT_MEANINGFUL | derived |